Skip to content

In the BioHarmony Drug Report Database

Sotagliflozin

Zynquista (sotagliflozin) is a small molecule pharmaceutical. Sotagliflozin was first approved as Zynquista on 2019-04-26. It has been approved in Europe to treat type 1 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1.
Trade Name Zynquista
Common Name Sotagliflozin
Indication type 1 diabetes mellitus
Drug Class Phlorozin derivatives, phenolic glycosides
Sotagliflozin
Get full access now